Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 SEK | +0.58% | +13.82% | -32.95% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 7.19 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.95% | 13.51M | D | ||
-27.70% | 9.88B | A- | ||
+27.06% | 2.89B | D+ | ||
-16.78% | 2.88B | C | ||
-15.31% | 2.12B | - | B- | |
-21.41% | 1.67B | C+ | ||
+68.70% | 1.45B | B- | ||
+29.75% | 788M | C- | ||
-5.02% | 741M | C+ | ||
-29.39% | 514M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOVIC B Stock
- Ratings Biovica International AB